TECX Tectonic Therapeutic Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: TECX

Price (delayed)

$24.98

Market cap

$488.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.57

Enterprise value

$265.19M

?
Relative Growth: Rel. Growth: 2
Relative Strength: Rel. Strength: 58
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4

AVROBIO, Inc. is a leading, Phase 2 gene therapy company focused on the development of its investigational gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs ...

Highlights
TECX's debt has surged by 126% year-on-year but it is down by 5% since the previous quarter
Tectonic Therapeutic's quick ratio has increased by 20% from the previous quarter but it has decreased by 13% YoY
The EPS has dropped by 59% year-on-year and by 2.5% since the previous quarter
TECX's net income is down by 30% year-on-year and by 2.8% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.avrobio.com
Peers: VIVS ORIC ORMP

Key stats

What are the main financial stats of TECX

TECX stock price

How has the Tectonic Therapeutic stock price performed over time
Intraday
-5.74%
1 week
-10.5%
1 month
-33.62%
1 year
65.32%
YTD
19.75%
QTD
-27.33%

Financial performance

How have Tectonic Therapeutic's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$94.93M
Net income
-$85.79M
Gross margin
N/A
Net margin
N/A
TECX's net income is down by 30% year-on-year and by 2.8% since the previous quarter
TECX's operating income is down by 28% year-on-year and by 2% since the previous quarter

Price vs fundamentals

How does TECX's price correlate with its fundamentals

Growth

What is Tectonic Therapeutic's growth rate over time

Valuation

What is Tectonic Therapeutic stock price valuation
P/E
N/A
P/B
2.11
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 59% year-on-year and by 2.5% since the previous quarter
TECX's price to book (P/B) is 72% more than its 5-year quarterly average of 1.3 and 12% more than its last 4 quarters average of 2.0
Tectonic Therapeutic's equity has decreased by 21% YoY and by 2.9% from the previous quarter

Efficiency

How efficient is Tectonic Therapeutic business performance
The return on assets has declined by 19% year-on-year and by 9% since the previous quarter
Tectonic Therapeutic's ROE has decreased by 17% YoY and by 9% from the previous quarter

Dividends

What is TECX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TECX.

Financial health

How did Tectonic Therapeutic financials performed over time
The total assets has declined by 20% year-on-year and by 3.9% since the previous quarter
TECX's current ratio is up by 20% QoQ but it is down by 13% YoY
TECX's debt is 98% smaller than its equity
TECX's debt has surged by 126% year-on-year but it is down by 5% since the previous quarter
The debt to equity has soared by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.